Oculis Holding AG (OCS)
Here's Why Momentum in Oculis Holding AG (OCS) Should Keep going
Oculis Holding AG (OCS) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
Oculis Is An Interesting Growth Bet On Non-Invasive Eye Care
Oculis' main value driver appears to be OCS-01, which targets a respectable $4 billion DME TAM with its non-invasive eye drops. Eye injections are tough on patients, so this bodes well for OCS-01. OCS-05 and OCS-02 also target interesting TAMs in neuro-ophthalmology and DMD. OCS's cash runway should last until late 2026, but if they don't generate an FDA-approved product soon, it could become an issue for shareholders.
Oculis Holding AG (OCS) Reports Q3 Loss, Lags Revenue Estimates
Oculis Holding AG (OCS) came out with a quarterly loss of $0.55 per share versus the Zacks Consensus Estimate of a loss of $0.52. This compares to loss of $0.38 per share a year ago.
Oculis Holding AG (OCS) Moves 7.9% Higher: Will This Strength Last?
Oculis Holding AG (OCS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Oculis Holding AG (OCS) Surges 8.2%: Is This an Indication of Further Gains?
Oculis Holding AG (OCS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Oculis Holding AG (OCS) Reports Q2 Loss, Misses Revenue Estimates
Oculis Holding AG (OCS) came out with a quarterly loss of $0.56 per share versus the Zacks Consensus Estimate of a loss of $0.43. This compares to loss of $0.42 per share a year ago.
